Publications by authors named "Rabab M Maher"
Potential Diagnostic Role of Serum Fibroblast Growth Factor-19 in Hepatocellular Carcinoma.
Asian Pac J Cancer Prev
September 2024
Article Synopsis
- A study was conducted to evaluate the potential of Fibroblast Growth Factor-19 (FGF-19) as a new diagnostic biomarker for hepatocellular carcinoma (HCC), aiming to enhance diagnostic accuracy and improve patient survival rates.
- The research included 114 participants divided into three groups (HCC, Cirrhosis, and Control), revealing that FGF-19 levels were significantly different among the groups, with FGF-19 showing 100% sensitivity and specificity for distinguishing HCC from healthy controls.
- The findings suggest that FGF-19 could be a valuable noninvasive serum biomarker for HCC, particularly when used alongside other markers like alpha-fetoprotein (AFP
Introduction: After hepatocellular carcinoma (HCC) interventional therapies, noninvasive vascular diagnostic imaging [duplex, Color/power Doppler ultrasonography, and triphasic computed tomography (CT)] determines the lesion complete/incomplete ablation. The aim was to analyze the usefulness of duplex, color/power Doppler ultrasonography in HCC ablation after percutaneous ablative therapies (PATs).
Methods: We included 30 patients with 33 HCCs subjected to duplex/Doppler ultrasonography, ultrasound-guided fine-needle aspiration cytology (FNAC), and triphasic CT, all these before and after PATs.
Background: Hepatitis C virus (HCV) is a major health problem in Egypt, with a high prevalence of genotype 4.
Aim: This study aimed to evaluate the safety and efficacy of generic sofosbuvir (SOF) plus generic daclatasvir (DAC) with or without ribavirin in the treatment of Egyptian chronic HCV patients compared with the use of brand drugs.
Materials And Methods: An observational study that included 234 Egyptian chronic HCV patients was carried out.